Actively Recruiting
Study of Fertility Effects in Women Under 40 With Resected Melanoma Receiving Adjuvant Therapy Including Dabrafenib, Trametinib, Pembrolizumab, or Nivolumab
Led by Intergruppo Melanoma Italiano · Updated on 2025-09-05
270
Participants Needed
10
Research Sites
208 weeks
Total Duration
AI-Summary
What This Trial Is About
Melanoma survivorship among women of reproductive age is increasing due to more effective treatments. This research aims to understand how newer melanoma therapies, specifically MAP kinase pathway inhibitors and immune-checkpoint inhibitors ICIs, affect fertility and ovarian function. The study responds to limited data about the impact of these treatments on reproductive health, focusing on women with resected melanoma at high risk of relapse. Participants will be observed in three groups those receiving BRAFMEK inhibitors Dabrafenib plus Trametinib, those receiving ICIs such as Pembrolizumab or Nivolumab, and those under observation without adjuvant therapy. The treatments are used as per standard clinical practice, and the study monitors fertility outcomes without altering the clinical application of these drugs. Women enrolled will be followed over time with blood tests measuring serum antimullerian hormone AMH at 3, 12, and 18 months after starting therapy to assess ovarian reserve and fertility preservation. The study evaluates both early and long-term effects of adjuvant treatments on fertility. Participants reproductive outcomes will be closely monitored during this prospective observational study conducted by Intergruppo Melanoma Italiano.
CONDITIONS
Brief Title
MELAFERT: Impact of Adjuvant Therapy on FERTility in Patients With Resected MELAnoma at High Risk of Relapse.
Research Team
M
Mario Mandalà
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here